Table II. Overview on DC immunotherapy in ovarian cancer.
| Author | Tumorantigen | Type of immunotherapy | Number of patients | Clinical outcome |
| Brossart 2000 | MUC-1 or HER-2 | DC + peptide | 3 | 1 : SD > 8m; 1 SD during 8 w |
| Hernando 2002 | Lysate + KLH | DC + lysate and KLH | 6 | 3 SD |
| Loveland 2006 | mannan-MUC1 fusionprotein | DC + peptide | 1 | SD |
| Homma 2006 | Tumor cells | DC/tumor-fusie vaccin + rhIL-12 | 4 | Only available in 1 patient: PD with transient decease of CA125 |
| Hernando 2007 | α-FR | DC + mRNA-α-FR | 1 | PR |
| Peethambaram 2009 | HER-2 | Mix of PBMC and DC + a recombinant fusion antigen of HER2 | 4 | 2 SD |
| Chu 2012 | HER2-neu + hTERT + PADRE | DC + peptide +/- cyclophosphamide 2 days prior to vaccination + pneumococcal vaccination | 11 | 2 PD during vaccination, 3 PD between 6-26 m follow up, 6 CR |
| Rahma 2012 | P53 | Peptide + IL2 SC vs DC + peptide + IL2 IV | 21 | 4 NED after 2y, 16 PD |
| Kandalaft 2013 | Lysate | A/ In 6 patients: IV bevacizumab + metronomic cyclophosphamide PO, followed by bevacizumab + lysate loaded DC B/ In 3/6 patients this was followed by 1/ lymphodepletion + 2/ transfer of autologous T cells in combination with the vaccin |
6 | A/ 2 PR, 2 SD, 2 PD B/ 1 PR, 1 SD, 1 PD |
| Coosemans 2013 | WT1 | DC + mRNA-WT1 | 2 | PD with prolonged OS if chemotherapy was administered after immunotherapy stop |
| Mitchell 2014 | MUC-1 | DC + peptide | 26 | Decrease in CA125 in 5 patients, of which 2 PD, 2 PR, 1 CR |
| Kobayashi 2014 | WT1, MUC-1, CA125 | DC + peptide | 56 | After 3m: 32 PD, 14 SD, 2 PR, 8 not evaluable |
| Bapsy 2014 | Lysate | DC + lysate IV | 7 | 4 PD, 2 SD, 1 PR |
CR, complete remission; CA125, cancer antigen 125; DC, dendritic cell; IL, interleukin; KHL, keyhole limpet hemocyanin; MUC-1, mucin 1; mRNA, messenger ribonucleic acid; NED, no evidence of disease; PBMC, peripheral blood mononuclear cell; OS, overall survival; PD, progressive disease; PR, partial remission; rh, recombinant human; SC: subcutaneous; SD, stable disease; TAA, tumor-associated antigen; TERT, telomerase reverse transcriptase; WT1, Wilms’ tumor gene 1; y, year; m, month; w, weeks;SC, subcutaneous; IV, intravenous; PO, orally; HER-2, human epidermal growth factor 2; PADRE, DR-restricted Th helper epitope.